Plasminogen: An important hemostatic parameter in septic patients
Background: Previously we observed in some but not all septic patients a low plasma concentration of plasminogen. Objectives: To investigate prospectively whether plasma levels of plasminogen or the ratio of plasminogen to alpha-2-antiplasmin have a prognostic value for survival from sepsis and to s...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
1997
|
| Materias: | |
| Acceso en línea: | Registro en Scopus Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 11157caa a22012137a 4500 | ||
|---|---|---|---|
| 001 | PAPER-3257 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518203243.0 | ||
| 008 | 190411s1997 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0030759271 | |
| 024 | 7 | |2 cas |a Antiplasmin; Plasminogen, 9001-91-6 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a THHAD | ||
| 100 | 1 | |a Duboscq, C. | |
| 245 | 1 | 0 | |a Plasminogen: An important hemostatic parameter in septic patients |
| 260 | |c 1997 | ||
| 270 | 1 | 0 | |m Kordich, L.; Dpto de Quimica Biologica, Facultad Ciencias Exactas Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Bone, R.C., Balk, R.A., Cerra, F.B., Dellinger, R.P., Fein, A.M., Knaus, W.A., Schein, R.M., Sibbad, W., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis (1992) Chest, 10, pp. 1644-1655. , The American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee | ||
| 504 | |a Bone, R.C., The pathogenesis of sepsis (1991) Ann Intern Med, 115, pp. 457-469 | ||
| 504 | |a Coalson, J.J., Pathology of sepsis, septic shock and multiple organ failure (1986) Perspective on Sepsis and Septic Shock, pp. 27-57. , Sibbald WJ, Sprung CL (eds). Society of Critical Care Medicine. Fullefon CA | ||
| 504 | |a Philippé, J., Offner, F., Declerck, P.J., Leroux-Roels, G., Vogelaers, D., Basele, G., Collen, D., Fibrinolysis and coagulation in patients with infectious disease and sepsis (1991) Thromb Haemost, 65, pp. 291-295 | ||
| 504 | |a Hesselvik, F.J., Blombäck, M., Brodin, B., Mailer, R., Coagulation, Fibrinolysis and Kallikrein systems in sepsis: Relation to outcome (1989) Crit Care Med, 17, pp. 724-733 | ||
| 504 | |a Dofferhoff, A.S., Bom, V.J., De Vries-Hospers, H.G., Van Ingen, J., Van De Meer, J., Hazenberg, B.P., Mulder, P.O., Weits, J., Pattern of cytokines, plasma endotoxin, plasminogen activator inhibition and acute-phase proteins during the treatment of severe sepsis in human (1992) Crit Care Med, 20, pp. 185-192 | ||
| 504 | |a Salgado, A., Boveda, J.L., Monasterio, J., Segura, R.M., Mourelle, M., Gomez-Jimenez, J., Peracaula, R., Inflammatory mediators and their influence on haemostasis (1994) Haemost, 24, pp. 132-138 | ||
| 504 | |a Silverman, P., Goldsmith, G.H., Spitzer, T.R., Rehmus, E.H., Berger, N.A., Effect of tumor necrosis factor on the human fibrinolytic system (1990) J Clinical Oncology, 8, pp. 468-475 | ||
| 504 | |a Hellgren, M., Egberg, N., Klund, E.J., Blood Coagulation and fibrinolytic factors and their inhibitors in critically ill patients (1984) Intens Care Med, 10, pp. 23-28 | ||
| 504 | |a Seitz, R., Wolf, M., Egbring, R., Radtke, K.P., Leisenfeld, A., Pittner, P., Havemam, K., Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections (1987) Eur J Haematology, 38, pp. 231-240 | ||
| 504 | |a Plow, E.F., The major fibrinolytic proteases of human leukocytes (1980) Biochim Biophys Acta, 630, pp. 47-56 | ||
| 504 | |a Moroz, L., Miniplasminogen: A mechanism for leukocyte modulation of plasminogen activation by urokinase (1981) Blood, 103, pp. 58-97 | ||
| 504 | |a Machovich, R., Owen, W., The elastase mediated pathway of fibrinolysis (1990) Blood Coagulation and Fibrinolysis, 1, pp. 79-90 | ||
| 504 | |a Christensen, U., Sottrup-Jensen, L., Magnusson, S., Petersen, T., Clemmensen, I., Enzymic properties of the neoplasmin -val 442 (miniplasmin) (1979) Biochim Biophy Acta, 567, pp. 472-481 | ||
| 504 | |a Kordich, L.C., Porterie, V.P., Lago, O., Bergonzelli, G.E., Sassetti, B., Sanchez Avalos, J.C., Mini-plasminogen like molecule in septic patients (1987) Thromb Res, 47, pp. 553-560 | ||
| 504 | |a Molinas, F.C., Kordich, L.C., Porterie, P., Lerner, G., Maiztegui, J.I., Plasminogen abnormalities in patients with Argentine hemorrhagic fever (1987) Thromb Res, 48, pp. 713-720 | ||
| 504 | |a Deutsch, D.G., Mertz, E.T., Plasminogen: Purification from human plasma by affinity chromatography (1970) Science, 170, pp. 1095-1096 | ||
| 504 | |a Laemmli, U.K., Cleavage of structural proteins during assembly of the head of bacteriophage T4 (1970) Nature, 227, pp. 680-685 | ||
| 504 | |a Towbin, H., Stochelim, T., Gordon, J., Electrophoretic transfer of proteins from polyacrilamide gels to nitrocelulose sheets: Procedure and some applications (1979) Proc Natl Acad Sci USA, 76, pp. 4350-4354 | ||
| 504 | |a Zweig, M.H., Campbell, G., Receiver-Operating Characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine (1993) Clin Chem, 39, pp. 561-577 | ||
| 504 | |a Pralong, G., Calandra, T., Glauser, M.P., Schellekens, J., Verhoef, J., Bachmann, F., Kruithof, E.K.O., Plasminogen activator inhibitor 1: A new prognostic marker in septic shock (1989) Thromb Haemost, 61, pp. 459-462 | ||
| 504 | |a Maestries, J.C., Kruithof, E.K.O., Marie-Paule Gascon, M.P., Herodin, F., Agay, D., Ythier, A., In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin 6 in baboons (1994) Eur Cytokine Netw, 5, pp. 275-281 | ||
| 504 | |a Kluft, C., Verheyen, J.H., Jie, A.F.H., Rijken, D.C., Preston, F.E., Sue Ling, H.M., Jespersen, J., Aasen, A.O., The postoperative fibrinolytic shutdown: A rapidly reverting acute phase patterns for the fast-acting inhibitor of tissue-type plasminogen activator after trauma (1985) Scand J Clin Lab Invest, 45, pp. 605-610 | ||
| 504 | |a Lorente, J.A., Garcia-Frade, L.J., Landin, M., De Pablo, R., Torrado, C., Renes, E., Garcia Avello, A., Time course of hemostatic abnormalities in sepsis and its relation to outcome (1993) Chest, 103, pp. 1536-1542 | ||
| 504 | |a Kruithof, E.K.O., Calandra, T., Pralong, G., Heumann, D., Gérain, J., Baumgartner, J.D., Bachmann, F., Glause, M.P., Evolution of plasminogen activator inhibitor type 1 in patients with septic shock - Correlation with cytokine concentrations (1993) Fibrinolysis, 7, pp. 117-121 | ||
| 504 | |a Massignon, D., Lepape, A., Bienvenu, J., Barbier, B., Boileau, C., Coeur, P., Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state (1994) Haemostas, 24, pp. 36-48 | ||
| 504 | |a Philippe, J., Dooijewaard, G., Offner, F., Turion, P., Baele, G., Leroux-Roels, G., Granulocyte elastase, tumor necrosis factor-alpha and urokinase levels as prognostic markers in severe infection (1992) Thromb Haemost, 68, pp. 19-23 | ||
| 504 | |a Nuijens, J.H., Abbink, J.J., Wachtfogel, Y.T., Colman, R.W., Eerenberg, A.J., Dors, D., Kamp, A.J., Hack, C.E., Plasma elastase alpha-1-antitrypsin and lactoferrin in sepsis: Evidence for neutrophils as mediators in fatal sepsis (1992) J Lab Clin Med, 119, pp. 159-168 | ||
| 520 | 3 | |a Background: Previously we observed in some but not all septic patients a low plasma concentration of plasminogen. Objectives: To investigate prospectively whether plasma levels of plasminogen or the ratio of plasminogen to alpha-2-antiplasmin have a prognostic value for survival from sepsis and to study the variation of other hemostatic parameters during septicemia. Patients: The study population consisted of 45 consecutive patients with septicemia, 15 non-septic patients from the same intensive care unit and 30 healthy volunteers. Measurements and Main Results: Plasminogen concentrations were significantly lower (p < 0.001) in plasma of septic patients (median 0,62 IU/ml range: 0.15-1,06) than in plasma of healthy controls (median 1.00 IU/ml, range: 0.75-1.10) or of non-septic intensive care patients (median 1.00 IU/ml, range: 0.82-1.08). Among the other parameters tested, plasminogen activator inhibitor (PAI-1) antigen concentration and PAI activity were similar in septic and non-septic intensive care patients, but higher than in healthy controls. Concentrations of elastase-alpha-1-protease inhibitor or of thrombin-antithrombin complexes were higher in septic patients than in non-septic intensive care patients or healthy controls. A degraded form of plasminogen of 38 kDa was detected by Western blot analysis in the plasma of septic patients, but not in plasma of non-septic intensive care patients or controls. Plasminogen alone or the ratio of plasminogen to antiplasmin were good markers for survival from septicemia. E.g. for plasminogen at a cut off of 0.65 IU/ml, sensitivity was 90.5% and specificity 66.7%, whereas for the ratio of plasminogen over antiplasmin at a cut off ratio of 0,65 IU/ml, sensitivity was 95.2% and specificity 70.8%. Conclusion: Plasminogen or the ratio of plasminogen to antiplasmin are sensitive markers for survival in patients with septicemia. |l eng | |
| 593 | |a Dpto. de Quim. Biológica, Fac. de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina | ||
| 593 | |a Gastroenterology Division, University Hospital, Lausanne, Switzerland | ||
| 593 | |a Department of Critical Care, Hospital Privado Güemes, Buenos Aires, Argentina | ||
| 593 | |a Division of Angiology and Hemostasis, University Hospital, Geneva, Switzerland | ||
| 690 | 1 | 0 | |a ALPHA 2 ANTIPLASMIN |
| 690 | 1 | 0 | |a ANTIPLASMIN |
| 690 | 1 | 0 | |a ANTITHROMBIN |
| 690 | 1 | 0 | |a ELASTASE ALPHA 1 PROTEASE INHIBITOR |
| 690 | 1 | 0 | |a ELASTASE INHIBITOR |
| 690 | 1 | 0 | |a PLASMINOGEN |
| 690 | 1 | 0 | |a PLASMINOGEN ACTIVATOR INHIBITOR |
| 690 | 1 | 0 | |a THROMBIN |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a ADULT |
| 690 | 1 | 0 | |a AGED |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a BLOOD CLOTTING |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a ENZYME ACTIVITY |
| 690 | 1 | 0 | |a FIBRINOLYSIS |
| 690 | 1 | 0 | |a HEMOSTASIS |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a IMMUNOBLOTTING |
| 690 | 1 | 0 | |a INTENSIVE CARE |
| 690 | 1 | 0 | |a MAJOR CLINICAL STUDY |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a PROGNOSIS |
| 690 | 1 | 0 | |a PROTEIN BLOOD LEVEL |
| 690 | 1 | 0 | |a PROTEIN DEGRADATION |
| 690 | 1 | 0 | |a SEPSIS |
| 690 | 1 | 0 | |a ADULT |
| 690 | 1 | 0 | |a AGED |
| 690 | 1 | 0 | |a ANTIPLASMIN |
| 690 | 1 | 0 | |a HEMOSTASIS |
| 690 | 1 | 0 | |a HUMANS |
| 690 | 1 | 0 | |a MIDDLE AGED |
| 690 | 1 | 0 | |a PLASMINOGEN |
| 690 | 1 | 0 | |a PROGNOSIS |
| 690 | 1 | 0 | |a PROSPECTIVE STUDIES |
| 690 | 1 | 0 | |a SEPSIS |
| 650 | 1 | 7 | |2 spines |a SEPTICEMIA |
| 700 | 1 | |a Quintana, I. | |
| 700 | 1 | |a Bassilotta, E. | |
| 700 | 1 | |a Bergonzelli, G.E. | |
| 700 | 1 | |a Porterie, P. | |
| 700 | 1 | |a Sassetti, B. | |
| 700 | 1 | |a Haedo, A.S. | |
| 700 | 1 | |a Wainsztein, N. | |
| 700 | 1 | |a Kruithof, E.K.O. | |
| 700 | 1 | |a Kordich, L. | |
| 773 | 0 | |d 1997 |g v. 77 |h pp. 1090-1095 |k n. 6 |p THROMB. HAEMOST. |x 03406245 |t Thrombosis and Haemostasis | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030759271&partnerID=40&md5=c04d6e0562dbb49fc9240657a7139ae5 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_03406245_v77_n6_p1090_Duboscq |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03406245_v77_n6_p1090_Duboscq |y Registro en la Biblioteca Digital |
| 961 | |a paper_03406245_v77_n6_p1090_Duboscq |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 64210 | ||